Checchi Capital Advisers’s Genmab GMAB Stock Holding History

Checchi Capital Advisers’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,905	Closed	-$200K	–	533
2021 Q2	$200K	Buy	+4,905	New	+$189K	0.02%	507
2021 Q1	–	Sell	-5,566	Closed	-$226K	–	528
2020 Q4	$226K	Sell	5,566 -139	-2%	-$5.2K	0.02%	424
2020 Q3	$209K	Buy	+5,705	New	+$206K	0.02%	400

Other funds holding GMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Checchi Capital Advisers's GMAB Position: Q3 2021 in Review

Checchi Capital Advisers sold out of Genmab (GMAB) in Q3 2021, closing a stake of 4,905 shares — an estimated $200K sold.

Checchi Capital Advisers first reported a position in GMAB in Q3 2020 and held it in 3 quarters. The position peaked at $226K in Q4 2020. 211 funds tracked by Wall St. Rank hold GMAB as of Q3 2021.

Checchi Capital Advisers reported no remaining Genmab position as of Q3 2021 after selling out during the quarter.
Checchi Capital Advisers sold 4,905 Genmab shares in Q3 2021, an estimated $200K.
Checchi Capital Advisers first reported a position in Genmab in Q3 2020 and held it in 3 quarters.
Checchi Capital Advisers's Genmab position peaked at $226K in Q4 2020.
211 funds tracked by Wall St. Rank held Genmab as of Q3 2021.

Based on Checchi Capital Advisers's 13F filing for Q3 2021, filed 9 Nov 2021.